Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
University of California, Irvine
Immatics US, Inc.
Acepodia Biotech, Inc.
Adaptimmune
BioEclipse Therapeutics
Gilead Sciences
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
BGI, China
Genocea Biosciences, Inc.
GlaxoSmithKline